These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 32707358

  • 1. Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: Results of multicenter study in Japan.
    Ieko M, Ohmura K, Naito S, Yoshida M, Sakuma I, Ikeda K, Ono S, Suzuki T, Takahashi N.
    Thromb Res; 2020 Nov; 195():158-164. PubMed ID: 32707358
    [Abstract] [Full Text] [Related]

  • 2. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, Bassi L, Carraro P, Cini M, Paniccia R, Poli D, Palareti G.
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [Abstract] [Full Text] [Related]

  • 3. Bleeding After Gastric Endoscopic Submucosal Dissection Focused on Management of Xa Inhibitors.
    Ono S, Ieko M, Tanaka I, Shimoda Y, Ono M, Yamamoto K, Sakamoto N.
    J Gastric Cancer; 2022 Mar; 22(1):47-55. PubMed ID: 35425658
    [Abstract] [Full Text] [Related]

  • 4. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
    Morishima Y, Kamisato C.
    Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S.
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M, Birschmann I, Peter A, Spencer C, Härtig F, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S.
    Crit Care; 2017 Feb 15; 21(1):32. PubMed ID: 28196509
    [Abstract] [Full Text] [Related]

  • 11. Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors.
    Ono R, Nishimura K, Takahashi H, Hori Y, Fukushima K, Kobayashi Y.
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb 15; 396(2):323-336. PubMed ID: 36326895
    [Abstract] [Full Text] [Related]

  • 12. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K.
    Pathology; 2016 Jan 15; 48(1):60-71. PubMed ID: 27020211
    [Abstract] [Full Text] [Related]

  • 13. Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa.
    Bourdin M, Perrotin D, Mathieu O, Herve T, Depasse F, Lu G, Conley PB, Contant G.
    Int J Lab Hematol; 2021 Aug 15; 43(4):795-801. PubMed ID: 34092030
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the Correlation Between Coagulation Indices and Rivaroxaban Concentrations.
    Wu T, Wu S, Li M, Zhang J.
    Ann Pharmacother; 2024 Jan 15; 58(1):28-36. PubMed ID: 37125735
    [Abstract] [Full Text] [Related]

  • 15. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
    Gay J, Duchemin J, Imarazene M, Fontenay M, Jourdi G.
    Int J Lab Hematol; 2019 Dec 15; 41(6):738-744. PubMed ID: 31487115
    [Abstract] [Full Text] [Related]

  • 16. Anticoagulant activity of oral rivaroxaban in healthy dogs.
    Conversy B, Blais MC, Dunn M, Gara-Boivin C, Del Castillo JRE.
    Vet J; 2017 May 15; 223():5-11. PubMed ID: 28671072
    [Abstract] [Full Text] [Related]

  • 17. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L, Lukes J, Friedecky D, Zhanelova M, Nemcova M, Ulehlova J, Prochazkova J, Hlusi A, Palova M, Vaclavik J.
    Clin Lab; 2018 Oct 01; 64(10):1611-1621. PubMed ID: 30336535
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
    Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW.
    J Thromb Haemost; 2014 Nov 01; 12(11):1810-5. PubMed ID: 25196577
    [Abstract] [Full Text] [Related]

  • 20. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
    Miklič M, Mavri A, Vene N, Söderblom L, Božič-Mijovski M, Pohanka A, Antovic J, Malmström RE.
    Eur J Clin Pharmacol; 2019 Aug 01; 75(8):1069-1075. PubMed ID: 31139866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.